Oculis (NASDAQ:OCS - Get Free Report) announced its quarterly earnings data on Tuesday. The company reported ($0.76) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.28), Zacks reports. Oculis had a negative return on equity of 71.31% and a negative net margin of 8,043.28%.
Oculis Stock Up 0.5 %
OCS stock traded up $0.10 during mid-day trading on Tuesday, hitting $18.40. 59,598 shares of the company were exchanged, compared to its average volume of 44,810. The firm has a market cap of $745.27 million, a P/E ratio of -9.53 and a beta of 0.01. Oculis has a 1-year low of $10.55 and a 1-year high of $23.08. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.02 and a current ratio of 4.02. The firm's 50 day simple moving average is $20.79 and its 200 day simple moving average is $16.82.
Analyst Ratings Changes
A number of research firms recently weighed in on OCS. HC Wainwright reissued a "buy" rating and set a $30.00 price target on shares of Oculis in a research note on Monday, January 6th. Chardan Capital reaffirmed a "buy" rating and set a $28.00 target price on shares of Oculis in a report on Tuesday, January 7th.
Read Our Latest Analysis on Oculis
Oculis Company Profile
(
Get Free Report)
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Oculis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oculis wasn't on the list.
While Oculis currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
